Anti-KALRN monoclonal antibody

Pre-made anti-KALRN monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to KALRN/KALRN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1034-Ab-1/ GM-Tg-hg-IP1034-Ab-2Anti-Human KALRN monoclonal antibodyHuman
GM-Tg-rg-IP1034-Ab-1/ GM-Tg-rg-IP1034-Ab-2Anti-Rat KALRN monoclonal antibodyRat
GM-Tg-mg-IP1034-Ab-1/ GM-Tg-mg-IP1034-Ab-2Anti-Mouse KALRN monoclonal antibodyMouse
GM-Tg-cynog-IP1034-Ab-1/ GM-Tg-cynog-IP1034-Ab-2Anti-Cynomolgus/ Rhesus macaque KALRN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1034-Ab-1/ GM-Tg-felg-IP1034-Ab-2Anti-Feline KALRN monoclonal antibodyFeline
GM-Tg-cang-IP1034-Ab-1/ GM-Tg-cang-IP1034-Ab-2Anti-Canine KALRN monoclonal antibodyCanine
GM-Tg-bovg-IP1034-Ab-1/ GM-Tg-bovg-IP1034-Ab-2Anti-Bovine KALRN monoclonal antibodyBovine
GM-Tg-equg-IP1034-Ab-1/ GM-Tg-equg-IP1034-Ab-2Anti-Equine KALRN monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1034-Ab-1/ GM-Tg-hg-IP1034-Ab-2; GM-Tg-rg-IP1034-Ab-1/ GM-Tg-rg-IP1034-Ab-2;
GM-Tg-mg-IP1034-Ab-1/ GM-Tg-mg-IP1034-Ab-2; GM-Tg-cynog-IP1034-Ab-1/ GM-Tg-cynog-IP1034-Ab-2;
GM-Tg-felg-IP1034-Ab-1/ GM-Tg-felg-IP1034-Ab-2; GM-Tg-cang-IP1034-Ab-1/ GM-Tg-cang-IP1034-Ab-2;
GM-Tg-bovg-IP1034-Ab-1/ GM-Tg-bovg-IP1034-Ab-2; GM-Tg-equg-IP1034-Ab-1/ GM-Tg-equg-IP1034-Ab-2
Products NameAnti-KALRN monoclonal antibody
Formatmab
Target NameKALRN
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-KALRN monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1034-Ag-1Recombinant multi-species KALRN/ ARHGEF24/ CHD5 protein


    Target information

    Target IDGM-IP1034
    Target NameKALRN
    Gene ID8997,545156,84009,715567,101094783,540675,100060560
    Gene Symbol and Synonyms2210407G14Rik,ARHGEF24,CHD5,CHDS5,DUET,DUO,E530005C20Rik,Gm539,HAPIP,Kalirin,KALNC2,KALRN,TRAD
    Uniprot AccessionO60229,P97924
    Uniprot Entry NameKALRN_HUMAN,KALRN_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000160145
    Target ClassificationN/A

    The target: KALRN, gene name: KALRN, also named as ARHGEF24, CHD5, CHDS5, DUET, DUO, HAPIP, TRAD. Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein that interacts with the huntingtin-associated protein 1, which is a huntingtin binding protein that may function in vesicle trafficking. [provided by RefSeq, Apr 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.